Delving into the Latest Updates on Carbimazole with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Athyromazole, Carbethoxymethimazole, Carbimazole (INN)

+ [6]

Target

TPO

Action

inhibitors

Mechanism

TPO inhibitors(Thyroid peroxidase inhibitors)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

HyperthyroidismThyrotoxicosis

Inactive Indication-

Originator Organization

Tianjin Tianyao Pharmaceuticals Co., Ltd.

Active Organization

Amdipharm Mercury (Australia) Pty Ltd

Tianjin Tianyao Pharmaceuticals Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

Australia (23 May 2012),

HyperthyroidismThyrotoxicosis

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC7H10N2O2S

InChIKeyCFOYWRHIYXMDOT-UHFFFAOYSA-N

CAS Registry22232-54-8

To determine how thyroid status regulates the relationship between brown adipose tissue (BAT) volume/activity, white adipose tissue (WAT) partitioning and basal metabolic rate (BMR) in hyperthyroid patients transitioning to euthyroidism via antithyroid drugs.
To compare euthyroid outcomes (BAT, WAT, BMR, body composition, body weight and insulin resistance) achieved by hypothalamus-pituitary-thyroid (HPT) set point vs. normal ranges of plasma free thyroxine 4 (FT4) and throxine stimulating hormone (TSH).

Start Date13 Oct 2015

Sponsor / Collaborator

Agency for Science, Technology & Research

ACTRN12615000362594

/ SuspendedPhase 4

Comparing risk of relapse in Graves' disease patients treated with fixed-time carbimazole vs. treatment guided by TRAb titre

Start Date16 Jun 2015

Sponsor / Collaborator-

TCTR20170123003

/ CompletedNot ApplicableIIT

Effect of Adding Carbimazole to Levothyroxine on Outcome in Patients with Primary Hypothyroidism: A Preliminary Study

Start Date01 Jan 2015

Sponsor / Collaborator-

100 Clinical Results associated with Carbimazole

Login to view more data

100 Translational Medicine associated with Carbimazole

Login to view more data

100 Patents (Medical) associated with Carbimazole

Login to view more data

1,396

Literatures (Medical) associated with Carbimazole

17 Mar 2025·The Journal of Clinical Endocrinology & Metabolism

Data-Driven Strategies for Carbimazole Titration: Exploring Machine Learning Solutions in Hyperthyroidism Control

Article

Author: Budka, Dominika ; Bakirov, Rashid ; Smith, James ; Kelly, Derek ; Budka, Marcin ; Richardson, Tristan ; Reich, Thilo

AbstractBackgroundUniversity Hospitals Dorset (UHD) has more than 1000 thyroid patient contacts annually. These are primarily patients with autoimmune hyperthyroidism treated with carbimazole titration. Dose adjustments are made by a healthcare professional (HCP) based on the results of thyroid function tests, who then prescribes a dose and communicates this to the patient via letter. This is time consuming and introduces treatment delays. This study aimed to replace some time-intensive manual dose adjustments with a machine learning model to determine carbimazole dosing. This can in the future serve patients with rapid and safe dose determination and ease the pressures on HCPs.MethodsData from 421 hyperthyroidism patients at UHD were extracted and anonymized. A total of 353 patients (83.85%) were included in the study. Different machine learning classification algorithms were tested under several data processing regimes. Using an iterative approach, consisting of an initial model selection followed by a feature selection method, the performance was improved. Models were evaluated using weighted F1 scores and Brier scores to select the best model with the highest confidence.ResultsThe best performance is achieved using a random forest (RF) approach, resulting in good average F1 scores of 0.731. A model was selected based on a balanced assessment considering the accuracy of the prediction (F1 = 0.751) and the confidence of the model (Brier score = 0.38).ConclusionTo simulate a use-case, the accumulation of the prediction error over time was assessed. It was determined that an improvement in accuracy is expected if this model was to be deployed in practice.

15 Jan 2025·Cureus

Dilated Cardiomyopathy and Hyperthyroidism: A Case Report and Literature Review

Article

Author: Damoune, Ikram ; Chraibi, Abdelmajid ; Elgharnati, Oussama

Dilated cardiomyopathy (DCM) is a rare but potentially reversible complication of hyperthyroidism, often resulting from severe thyrotoxicosis, leading to ventricular dilatation and reduced systolic function. A 45-year-old patient presented with progressive dyspnea and peripheral edema. Laboratory tests and imaging confirmed hyperthyroidism-induced DCM with a reduced ejection fraction (30%). Treatment with carbimazole and propranolol resulted in the normalization of thyroid function and cardiac recovery within three months. Hyperthyroidism can induce cardiac remodeling through genomic and non-genomic mechanisms of thyroid hormones, leading to reversible DCM. Early diagnosis and management are essential to avoid long-term complications, as delayed treatment may result in irreversible myocardial damage. This case highlights the need for multidisciplinary collaboration.

31 Dec 2024·Annals of Medicine

A systematic review of the clinical characteristics and course of atrioventricular blocks in hyperthyroidism

Review

Author: Choudry, Hassan ; Tahir, Shuja ; Khan, Haseeb Ahmad ; Illigens, Ben ; Cerqueira, Tiago Lemos ; Khan, Adeel Ahmad ; Ata, Fateen

BACKGROUNDAtrioventricular block (AVB) is rare in hyperthyroidism (HTH). Little is known about the true prevalence, clinical course, optimal management, and outcomes of different types of AVBs in patients with HTH. To address these uncertainties, we aimed to conduct a systematic review by combining the available literature to provide more meaningful data regarding AVBs in HTH.METHODSWe systematically searched PubMed, Scopus, Embase, and Google Scholar for articles reporting patients who developed AVB in the context of HTH. Data were analysed in STATA 16. The main outcomes included types of AVB, frequency of pacemaker insertion, and resolution of AVB. The systematic review is registered with the International Prospective Register of Systematic Reviews (PROSPERO) with the identification number CRD42022335598.RESULTSA total of 56 studies (39 case reports, 12 case series, 3 conference abstracts, 1 retrospective study, and 1 prospective observational study) with 87 patients were included in the analysis, with a mean age of 39.1 ± 17.6 years. Females constituted 65.7% (n = 48) of the cohort. Complete heart block (CHB) was the most commonly reported AVB (N = 45, 51.7%), followed by first-degree AVB (16.1%) and second-degree AVB (14.9%). Overall, 21 patients underwent pacing. A permanent pacemaker was inserted in one patient with second-degree AVB and six patients with CHB. Mortality was reported in one patient with CHB. The clinical course and management of HTH and AVBs did not differ in patients with CHB or lower-degree blocks. Apart from lower rates of goitre and more use of carbimazole in those who underwent pacing, no differences were found when compared to the patients managed without pacing.CONCLUSIONCurrent data suggest that CHB is the most common type of AVB in patients with HTH. Most patients can be managed with anti-thyroid management alone. Additionally, whether pacemaker insertion alters the clinical outcomes needs further exploration.

100 Deals associated with Carbimazole

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D07616	Carbimazole	H03BB01	DB00389

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Thyrotoxicosis	Australia	Amdipharm Mercury (Australia) Pty Ltd	23 May 2012
Hyperthyroidism	China	Tianjin Tianyao Pharmaceuticals Co., Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ENDO2024	Not Applicable	Hyperthyroidism \| Agranulocytosis TSH receptor antibodies (TRAb)	-	Lithium	kdhywjozgi(gacezldchq) = Carbimazole-induced agranulocytosis mkwfqobmku (pcmcbqsopw ) View more	-	01 Jun 2024
				Carbimazole
ODP523 (ENDO2022)	Not Applicable	Thyroid Crisis \| Graves Disease CD52 \| thyroid peroxidase antibody	-	Alemtuzumab	iicjhidzsa(yktvynaakx) = The patient was agitated qhowqsprpg (qdvzfiqegr ) View more	-	01 Nov 2022
				Carbimazole
ESPE2021	Not Applicable	-	-	Methimazole or carbimazole	(wpjjfdlrxr) = yinbadyysv drutpqrpsj (gtvnjmfzxz ) View more	-	22 Sep 2021
ENDO2021	Not Applicable	Hyperthyroidism FT4 \| TSH	9	Carbimazole (Hyperthyroidism patients before treatment)	vizdzgbjgp(phieinbuln) = plasma kallikrein, protein glutamine gamma-glutamyl transferase, serpin B3 tsdcedyfbm (wrrgwuqlkf ) View more	-	03 May 2021
				Hyperthyroidism patients after Carbimazole treatment